Ascletis Pharma Inc. clinical trials

The registry lists 46 studies whose lead sponsor is Ascletis Pharma Inc. or one of 3 companies grouped under it. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.

Studies

Recruiting first, then most recently updated. Showing 46 of 46.

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or OverweightRecruitingNCT07893093Phase 1

  Sponsor listed in the registry: Ascletis Pharma (China) Co., Limited

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC36 Tablets for Oral Use in Adult Participants With Obesity or OverweightRecruitingNCT07893106Phase 1

  Sponsor listed in the registry: Ascletis Pharma (China) Co., Limited

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or OverweightRecruitingNCT07842640Phase 1

  Sponsor listed in the registry: Ascletis Pharma (China) Co., Limited

• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesRecruitingNCT07743463Phase 3

  Sponsor listed in the registry: Ascletis Pharma (China) Co., Limited

• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 DiabetesRecruitingNCT07743450Phase 3

  Sponsor listed in the registry: Ascletis Pharma (China) Co., Limited

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque PsoriasisCompletedNCT07024602Phase 1

  Sponsor listed in the registry: Ascletis Pharma (China) Co., Limited

• A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes MellitusCompletedNCT07321678Phase 2

  Sponsor listed in the registry: Ascletis Pharma (China) Co., Limited

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With ObesityCompletedNCT06679959Phase 1/2

  Sponsor listed in the registry: Ascletis Pharma (China) Co., Limited

• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid TumorsCompletedNCT05287399Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With SemaglutideCompletedNCT06972992Phase 1

  Sponsor listed in the registry: Ascletis Pharma (China) Co., Limited

• A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related ComorbiditiesCompletedNCT07002905Phase 2

  Sponsor listed in the registry: Ascletis Pharma (China) Co., Limited

• A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne VulgarisCompletedNCT06248008Phase 3

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne VulgarisCompletedNCT06192264Phase 3

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With ObesityCompletedNCT06680440Phase 1

  Sponsor listed in the registry: Ascletis Pharma (China) Co., Limited

• Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne VulgarisCompletedNCT05104125Phase 2

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Healthy and Obese SubjectsCompletedNCT06427590Phase 1

  Sponsor listed in the registry: Ascletis Pharma (China) Co., Limited

• Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASHActive, not recruitingNCT05462353Phase 2

  Sponsor listed in the registry: Gannex Pharma Co., Ltd.

• A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B PatientsCompletedNCT04465890Phase 2

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIVCompletedNCT05330143Phase 2

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Study to Evaluate Safety, Tolerability, PK and the Food Effect on PK of ASC11/RTV Tablets in Healthy SubjectsCompletedNCT05718518Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 PatientsWithdrawnNCT05596045Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBMActive, not recruitingNCT05118776Phase 3

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ASC42 in Healthy SubjectsCompletedNCT04679129Phase 1

  Sponsor listed in the registry: Gannex Pharma Co., Ltd.

• Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASHWithdrawnNCT05118360Phase 2

  Sponsor listed in the registry: Gannex Pharma Co., Ltd.

• Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese SubjectsCompletedNCT04686994Phase 1

  Sponsor listed in the registry: Gannex Pharma Co., Ltd.

• Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy VolunteersCompletedNCT04692025Phase 1

  Sponsor listed in the registry: Gannex Pharma Co., Ltd.

• DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.CompletedNCT04845646Phase 1

  Sponsor listed in the registry: Gannex Pharma Co., Ltd.

• Safety, Tolerability, and Pharmacokinetics of ASC43F, a Fixed Dose Combination Tablet in Healthy SubjectsCompletedNCT05118516Phase 1

  Sponsor listed in the registry: Gannex Pharma Co., Ltd.

• Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary CholangitisCompletedNCT05190523Phase 2

  Sponsor listed in the registry: Gannex Pharma Co., Ltd.

• Drug Interaction Study of ASC42 With AtorvastatinCompletedNCT05464628Phase 1

  Sponsor listed in the registry: Gannex Pharma Co., Ltd.

• Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBVCompletedNCT05107778Phase 2

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy SubjectsCompletedNCT05523141Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy SubjectsCompletedNCT04965337Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy SubjectsCompletedNCT04843449Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• A Study of the Relative Bioavailability of ASC41 in Healthy SubjectsCompletedNCT04527250Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China IIICompletedNCT03020082Phase 3

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• A Study of the Pharmacokinetics of ASC09F in Healthy SubjectsCompletedNCT04547894Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy VolunteersCompletedNCT04358523Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC TaiwanCompletedNCT03020095Phase 2

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.CompletedNCT03362814Phase 2/3

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy SubjectsCompletedNCT04352361Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China IICompletedNCT03020004Phase 2

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in ChinaCompletedNCT03430830Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers ChinaCompletedNCT03020134Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in ChinaCompletedNCT03288636Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.

• Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers ChinaCompletedNCT03019991Phase 1

  Sponsor listed in the registry: Ascletis Pharmaceuticals Co., Ltd.